Transitional Cells Carcinoma (TCC, Bladder cancer) comprises approximately 2% of all naturally occurring cancers in dogs, similar to rates in humans. With more than 70 million pet dogs in the United States and cancer developing in approximately 25% of older dogs, it is expected that bladder cancer will newly affect more than 20,000 dogs each year.
Our collaborators at University of Iowa developed a novel delivery system for chemotherapeutics for TCC, based on nanoparticles. This technology allows for the treatment(s) to be delivered locally into the bladder, and specifically target the tumor.
In this project, we want to test the safety and efficacy of this technique, by comparing the outcome of 2 groups of dogs affected by TCC:
· One group treated by intravesicalar (into the urinary bladder) administration of nanoparticules infused with an anti-cancer drug (vinblastine).
· One group treated by intravesicalar (into the urinary bladder) administration of the same anti-cancer drug (vinblastine) alone.
All groups will also be treated orally by Piroxicam (NSAID) during the entire trial, as standard of care
If you dog has been diagnosed with Bladder Transitional Cells Carcinoma, he may be eligible for this trial.
If you elect enrollment, this trial involves monthly visits at the Lloyd Veterinary Medical Center for 6 months for treatment administrations and tumor measurements.
If no improvement is detected after 2 months of treatment, your dog will be removed from the study and you will be offered standard of care treatment.
You will not have costs from your dog’s participation in this study.
You will be responsible for the treatment of any complications that may arise, and unrelated medical conditions.
You will not be compensated for your dog’s participation in this study.